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1. Introduction
Liver fibrosis results from chronic damage to the liver in conjunction with the accumulation
of extracellular matrix (ECM) proteins including collagen, which is a characteristic of most
types of chronic liver diseases (CLD) [1]. Hepatic fibrosis was historically thought to be a
passive and irreversible process due to the collapse of the hepatic parenchyma and its
substitution with a collagen-rich tissue [2, 3]. Currently, is recognised to be a dynamic process
that can progress or regress over periods as short as months [4].
This process is associated with an inflammatory response and a limited deposition of ECM. If
the hepatic injury persists, then eventually the liver regeneration fails, and hepatocytes are
substituted with abundant ECM. The distribution of this fibrous material depends on the origin
of the liver injury. In chronic viral hepatitis and chronic cholestatic disorders, the fibrotic tissue
is initially located around portal tracts, while in alcohol-induced liver disease, it locates in
pericentral and perisinusoidal areas [5]. As fibrotic liver diseases advance, the hepatic
architecture is distorted by the accumulation of ECM proteins leading to the formation of a
fibrous scar and the subsequent development of nodules of regenerating hepatocytes defines
cirrhosis. Main event in this process is the activation of the hepatic stellate cells, the main
collagen-producing cells, by fibrogenic cytokines. Other cells such as portal fibroblasts and
bone marrow–derived cells may also be involved in the fibrogenic process [1].
Liver biopsy is considered the current clinical standard of reference for the assessment of liver
fibrosis [6]. Histologic examination is useful in identifying the underlying cause of liver disease
and assessing the necro-inflammatory grade and the stage of fibrosis. However, it represents
an invasive procedure, with pain and major complications occurring in 40% and 0.5% of
patients, respectively [7]. Further, liver biopsy can be associated with substantial sampling-
error. Histologic examination is subject to intra- and inter-observer variation and does not
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predict disease progression [8]. Therefore, there is a need for reliable, simple, and non-invasive
methods for assessing liver fibrosis. In recent years, a wide variety of imaging-based methods
have been used for noninvasively assessing liver fibrosis, including ultrasound, CT and MRI.
In this chapter, we provide an overview of the newer imaging techniques used in the evaluation
of liver fibrosis.
2. Epidemiology and natural history
Fibrosis leading to cirrhosis can accompany virtually any CLD that is characterized by the
presence of architectural disruption and/or inflammation. Over many years the principle
causes of CLD have been chronic viral hepatitis B and alcoholic liver disease. Other etiologies
of liver disease include parasitic infestation (e.g. schistosomiasis), autoimmune attack on
hepatocytes or biliary epithelium, neonatal liver disease, metabolic disorders including
Wilson’s disease, hemochromatosis and a variety of storage diseases, chronic inflammatory
conditions (e.g. sarcoidosis), drug toxicity (e.g. methotrexate or hypervitaminosis A), and
vascular derangements, either congenital or acquired. While rates of alcoholism and alcoholic
liver disease are falling in many countries, hazardous drinking amongst young people is
resulting in alarming rates of alcoholic liver disease in several northern European countries [9,
10]. Over the last few decades two other diseases have emerged to make a major contribution
to the burden of CLD. Chronic hepatitis C and non-alcoholic fatty liver disease (NAFLD) are
recognised to have already had a major impact on CLD incidence. Hepatitis C virus (HCV) is
transmitted in blood and blood products through unsafe injection practices and the therapeutic
use of infected blood products. It is thought that the world prevalence of chronic hepatitis C
is nearly 200 million people [11, 12]. In the developed world with rapidly increasing rates of
obesity, NAFLD is considered to represent a major cause of significant fibrosis. Although it
appears that only a minority of patients with NAFLD (maybe 20%) develop significant fibrosis,
due to the vast prevalence of the at-risk overweight population, NAFLD may give rise to an
epidemic of liver fibrosis [13, 14].
Of the many causes of CLD, our understanding of natural history of fibrosis is most complete in
HCV, with some information about HBV and steatohepatitic diseases, including alcoholic liver
disease and NAFLD. Fibrosis associated with HCV can assume a variable course, from deca‐
des of viremia with tiny fibrosis to a rapid onset of cirrhosis within 10–15 years. It appears to be
host factors rather than viral factors that correlate with fibrosis progression in HCV, such as older
age at the time of infection, concurrent liver disease due to HBV or alcohol (>50g/day), male
gender, increased body mass index (BMI) and HIV infection or immunosuppression [15, 16].
Information about fibrosis progression in other diseases is largely subjective, but the devel‐
opment of cirrhosis typically requires many years to decades. There are, however, some
notable exceptions in which the development of cirrhosis can be greatly accelerated, possibly
occurring within months rather than years: (1) neonatal liver disease – infants with biliary
atresia may present at birth with severe fibrosis and marked parenchymal distortion; (2) HCV-
infected patients after liver transplantation – a subset of patients who undergo liver trans‐
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plantation for HCV cirrhosis may develop rapidly progressive cholestasis and recurrent
cirrhosis within months, requiring retransplantation [17]; (3) patients with HIV/HCV co-
infection – these patients have relatively rapid fibrosis compared to those with HCV alone [18],
especially if the HIV is untreated; (4) severe delta hepatitis [19]; and (5) some cases of drug-
induced liver disease. These examples of ‘fulminant fibrosis’ probably reflect dysregulation of
several pathways, including defective immunity, massive inflammation and necrosis, and/or
altered matrix resorption.
3. Assessment of stage of fibrosis
Liver biopsy is a common element of diagnostic workup in hepatic cirrhosis, and is the
accepted diagnostic gold standard. Several systems for scoring liver fibrosis have been
proposed in order to classify the progression of fibrosis to cirrhosis into discrete stages, each
based on visual assessment of collagen staining of liver biopsy samples. The more frequently
used systems are the histology activity index (HAI: Knodell score) [20], the Ishak modification
of the HAI score [21], and the Metavir score [22].
The HAI system consists of the evaluation of two histopathological categories, necroinflam‐
mation and fibrosis. Furthermore, necroinflammation includes three subcategories: periportal
necrosis and inflammation, scored from 0 to 10; intralobular necrosis and inflammation, scored
from 0 to 4; and portal inflammation, scored from 0 to 4. Fibrosis is scored as 0, 1, 3, or 4, with
1 indicating portal fibrosis only, 3 indicating bridging fibrosis, and 4 indicating cirrhosis. The
HAI score is the combined scores for necrosis, inflammation, and fibrosis, while the overall
HAI scores can also be broken into individual components of necrosis, inflammation, and
fibrosis to yield additional information [20]. Despite this system is widely used, is relatively
insensitive to changes in fibrosis (lack of a score for stages between mild and severe), and has
an intra- and inter-observer reproducibility relatively poor.
Ishak et al. [21] have proposed a modification of the HAI scoring system, which uses similar
scores for necroinflammatory changes (activity: 0 to 18), but scores fibrosis on a scale from 0
to 6. Scores of 1 and 2 indicate portal fibrosis, 3 and 4 bridging fibrosis, 5 incomplete or early
cirrhosis, and 6 established cirrhosis. The Ishak scale provides better discrimination in
assessing small changes in fibrosis, permitting a better assessment of progression of disease,
and possible effects of therapy. The intra- and interobserver variability of the Ishak scoring
system has yet to be carefully defined.
The Metavir score [22] was developed in an attempt to address some of the problems with the
Knodell score. The Metavir score is a semiquantitative classifications system and scores both
necroinflammatory changes that fibrosis. The activity score is graded according to the intensi‐
ty of necroinflammatory lesions (A0 = no activity, A1 = mild activity, A2 = moderate activity, A3
= severe activity). The fibrosis score is assessed on a five point scale (F0 = no fibrosis, F1 = portal
fibrosis without septa, F2 = few septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis)
(Figure 1). Clinically significant fibrosis is generally defined by F2 involvement or greater.
Compared to the Knodell fibrosis score (which has only four levels), the Metavir score permits
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recognition of subtler variation in the degree of fibrosis. The Metavir system has been carefully
validated and shows good intra- and interobserver reproducibility. This system is commonly
used in Europe. Table 1 compares the three systems described for evaluating the stage of fibrosis.
Figure 1. Progression of fibrosis from periportal fibrosis to cirrhosis according to the Metavir scoring system shown
through photomicrographs (original magnification, ×10; Hematoxylin and Eosin stains) of histologic sections from liv‐
er biopsy specimens. (a) No fibrosis (stage F0). (b) Portal and periportal fibrosis only (stage F1). (c) Periportal fibrosis
with few septa (stage F2). (d) Septal fibrosis and bridging without cirrhosis (stage F3). (e) Cirrhosis (stage F4) which
appears as nodules of liver parenchyma separated by thick fibrous bands.
Stage of fibrosis HAI (Knodell) Ishak Metavir*
0 No fibrosis No fibrosis No fibrosis
1
Portal fibrosis Fibrosis of isolated
portal areas with or without short septa
Portal fibrosis
2
n. d. Increased fibrosis
in most portal areas with or without short
septa
Portal fibrosis with scattered septa
3
Portoportal or portocentral
septa
Portal fibrosis with portoportal septa Numerous septa without cirrhosis
4
Cirrhosis Portal fibrosis Cirrhosis
with marked porportoportal or
portocentral septa
Cirrhosis
5
n. d. Marked septum formation (portoportal or
portocentral) with some nodule
formation (incomplete cirrhosis)
n. d.
6 n. d. Probable or definite cirrhosis n. d.
n. d. = not defined;
* only validated in chronic hepatitis C
Table 1. Histological classification systems for evaluating the stage of fibrosis
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According to the average size of the parenchymal nodules, cirrhosis may be classified into
micronodular, macronodular, and mixed types. While micronodular cirrhosis is defined as
nodules less than 0.3 cm in diameter, macronodular cirrhosis is defined as nodules larger than
0.3 cm. Micronodular cirrhosis is generally caused by diffuse liver injury, such as alcohol, other
hepatotoxic agents, and metabolic disorders (nonalcoholic steatohepatitis), whereas macro‐
nodular cirrhosis is observed in disease processes where hepatocellular regeneration plays a
significant role (chronic and autoimmune hepatitis) [23].
Although the scoring systems mentioned above for hepatic fibrosis are extremely useful in
diagnosis and staging of liver fibrosis, all of these systems have important limitations. Hepatic
fibrosis may not be homogenous throughout the liver, and the liver specimen obtained by the
needle biopsy may not accurately reflect the overall average degree of fibrosis. A number of
studies have demonstrated excessive rates of sampling error (25%-40%) resulting in poor
reproducibility regardless of underlying liver disease origin [24]. The extent of variation from
observer interpretation by expert histopathologists may be as high as 20% [25]. In addition,
there is mounting evidence that liver biopsy has a number of limitations for its use in these
roles as well. These include: (a) the effect of reduced biopsy size (<25 mm) and complete portal
tract number (<11) on understaging fibrosis; (b) interobserver variation in histological inter‐
pretation; and (c) the qualitative nature of assessing fibrosis in 2 dimensions with descriptive
staining techniques. Ultimately, the method of percutaneous liver biopsy is an invasive
procedure with poor acceptance by patients. The associated morbidity from this technique is
estimated at 3% with a mortality rate of 0.03% [26].
In summary, although liver biopsy is considered the standard of reference, it has several
limitations (invasiveness, complications, sampling variability, subjectivity) that restrict its role
as a method for screening and longitudinal assessment of liver fibrosis. New reproducible and
reliable noninvasive techniques are required to evaluate disease progression in patients with
CLD, and to monitor pharmacological treatment.
4. Imaging techniques
Since morphologic alterations and features of portal hypertension are present only in advanced
CLD, routine examinations by ultrasound (US), computed tomography (CT) and magnetic
resonance imaging (MRI) could produce specific findings, but with very limited sensitivity.
The ability to detect early and intermediate stages of fibrosis using conventional ultrasound
with Doppler assessment of the hepatic vasculature is unsatisfactory [27]. CT offers improved
resolution of early morphological changes with cirrhosis but has low accuracy in fibrosis
detection [28]. In fact, quantitative assessment of the density distribution of liver parenchyma
showed that only diffuse steatosis and active alcoholic cirrhosis had significantly different
mean hepatic attenuation values [29]. Moreover, most studies of contrast-enhanced CT
involved patients with cirrhosis [30, 31] and it is thus unclear if changes in hepatic enhancement
could be used to diagnose mild or moderate hepatic fibrosis. MRI identify specific features of
cirrhosis such as hepatic vein narrowing, caudate to right lobe ratio, and expanded gallbladder
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fossa [32], but remains lacking in earlier stages of fibrosis [33]. Hence, assiduous efforts have
been made to search for technological developments.
4.1. Sonography-based techniques for assessment of liver fibrosis
Recently, diverse sonography–based techniques have been used in assessment of liver fibrosis,
including Transient Elastography, Real-Time Elastography, and Acoustic Radiation Force
Imaging sonoelastography.
Transient Elastography. Transient Elastography (TE) (FibroScan®, Echosens, Paris, France) is
a new imaging modality for detecting hepatic fibrosis. The measuring instrument comprises
a computer driven control unit and a probe with an ultrasound transducer, which is located
at the end of a vibrating piston. The piston generates a low frequency elastic wave (5 Mhz) that
passes through the skin and liver tissue and is transmitted into hepatic tissue at a speed of
around 1 m/s. The ultrasound then detects the propagation of the shear wave through the liver
by measuring its velocity. The shear wave velocity is directly related to the tissue stiffness,
with a higher velocity equating to higher tissue stiffness, corresponding to increasing severity
of fibrosis.
TE is carried out with the patient supine, with his/her right arm behind their head. The
measuring probe is positioned at the level of the xiphoid in the right mid-axillary line, at 90
degrees to the body. TE measures liver stiffness in a volume that approximates a cylinder 1
cm wide and 4 cm long, between 2,5 cm and 6,5 cm below the skin surface (Figure 2). Ten
validated measurements are required, with the median value taken as the final result, which
is expressed in units of kilopascals (kPa). The range of possible liver stiffness values obtained
with this technique is from 2.5 to 75.0 kPa, with the normal liver stiffness value for healthy
individuals being around 5.5 kPa (Figure 3) [34].
Figure 2. Illustration of the two different constituent of the measuring instrument and the positioning of the probe in
relation to the area of liver under investigation.
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The advantages of TE are that the results are immediately available, and the procedure is
painless, rapid (~3 minutes per patient), and easy to perform. The interequipment, intraob‐
server (96–98%) and interobserver agreement (89–98%) of TE has been shown to be excellent,
but the success rate depends on observer expertise, patient BMI and intercostal space [35-37].
Moreover, TE is a reliable method for the diagnosis of extensive fibrosis (Metavir F=3) and
cirrhosis (F=4): positive and negative predictive values range from 70–95% and 77–95%,
respectively [38-41]. The age of the subject does not affect liver stiffness, and males tend to
have a slightly higher liver stiffness value compared to females [34]. One of the important
aspects of liver stiffness measurements is the cut-off values that are adopted for different stages
of fibrosis, with higher cut-off levels corresponding to higher fibrosis stages.
Figure 3. Example of shear wave propagation velocity in healthy subject with normal liver stifness.
The cut-off levels are also different for different diseases. Therefore it is important to interpret
the results with the cut-off values specific for the underlying condition. Table 2 show a
summary of the cut-off values used for specific liver diseases. For example, in HCV patients
according to Castera et al. [42], liver stiffness cut-off values were 7.1 kPa for F≥2, 9.5 kPa for
F≥3, and values ≥ 12.5 kPa for F=4 (defined according to Metavir system).
There are some physical limitations of TE, such as obesity (particularly the fatness of the chest
wall), narrow intercostal space and ascites. Moreover, Fraquelli et al. found that TE reprodu‐
cibility is significantly reduced in patients with steatosis, an increased BMI and lower degrees
of hepatic fibrosis [35]. TE is an innovative and user-friendly technology for the assessment of
hepatic fibrosis in patients with CLD. However, despite strong academic and commercial
promotion, the key reason that TE cannot completely substitute a liver biopsy is that it is unable
to diagnose liver disease and it only allows staging with the best diagnostic performances for
severe fibrosis and cirrhosis. Assessment of pre-cirrhotic disease and the longitudinal assess‐
ment of change in fibrosis have not been fully evaluated.
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Author Disease Cut-off F≥2
(kPa)
Cut-off F≥3
(kPa)
Cut-off F=4
(kPa)
Results
Castera et al. [42] HCV 7.1 9.5 12.5
AUROC for F≥2: 0.80
AUROC for F≥3: 0.90
AUROC for F=4: 0.95
Marcellin et al. [43] HBV 7.2 8.1 11.0
AUROC for F≥2: 0.81
AUROC for F≥3: 0.93
AUROC for F=4: 0.93
de Ledinghen et al. [44] HIV/HCVcoinfection 4.5 n.d. 11.8
AUROC for F≥2: 0.72
AUROC for F=4: 0.97
Yoneda M et al. [45] NAFLD 6.6 9.8 17.5
AUROC for F≥2: 0.87
AUROC for F≥3: 0.90
AUROC for F=4: 0.99
Corpechot C et al. [46] PBC or PSC 7.3 9.8 17.3
AUROC for F≥2: 0.92
AUROC for F≥3: 0.95
AUROC for F=4: 0.96
n. d. = not defined; PBC = primary biliary cirrhosis; PSC = primary sclerosing cholangitis.
Table 2. Diagnostic performance of TE for the diagnosis of cirrhosis according to liver disease
Real-Time Elastography. Real-Time Elastography (RTE) is an alternative method for meas‐
urement of tissue elasticity integrated in a sonography machine developed by Hitachi Medical
Systems. This technique can reveal the physical property of tissue using conventional ultra‐
sound probes during a routine sonography examination. Ophir et al. [47] first described the
principle of this technique in 1991. To reduce the time-consuming calculations, Pesavento et
al. [48] developed a fast cross-correlation technique that is the basis for RTE. The difference in
hardness between diseased and surrounding tissue can be detected by RTE based on the
physical properties of the tissue [49, 50]. In effect, this method measures the degree of tissue
distortion (strain), mechanically induced, in the B mode image to quantify the elasticity of the
tissue. By measuring the tissue strain induced by compression, it is possible to estimate the
tissue hardness. The calculation of tissue elasticity distribution is assessed in real-time
ultrasound imaging and depicted as color-coded images with the conventional B-mode image
in the background [49, 51]. The color scale includes the following colors: red (soft tissue), green
(intermediate, normal tissue), and blue (anelastic, hard tissue).
RTE is carried out with patients in a supine position with the right arm elevated above the head.
Breathing does not cause any motion artifacts since each elastography image is obtained in a few
milliseconds. The examination is performed on the right lobe of the liver through the intercos‐
tal space. 5-9 MHz probe is used because higher frequencies allow better analysis of areas close
to the transducer. The measurement depth is between 20 and 50 mm (mean, 35 mm) with a 350–
500 mm2 area of measurement. The results are considered consistent only applying a pressure of
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3–4 on a scale of 0–6 arbitrary units (Figure 4). Ten valid measurements are performed in each
subject and the entire examination lasts approximately 5–10 minutes per patient.
Friedrich-Rust et al. first assessed real-time elastography for the detection of liver fibrosis [52],
founding that the area under the receiver operating characteristic (AUROC), a measurement
of the diagnostic accuracy of a test, was 0.75 for the diagnosis of significant fibrosis (F≥2). A
significant increase in accuracy (AUROC = 0.93) was obtained by combining RTE score and
two routine laboratory values (platelet count and GGT). In a recent paper Wang et al. [53]
compared the overall elasticity determined by RTE in 55 patients with liver fibrosis and chronic
hepatitis B and in 20 healthy volunteers. Using a new quantitative technology for diffuse
histological lesion with 11 parameters characterizing the stiffness degree of tissue, the AUROC
was 0.93 (F≥1, p < 0.001) for the diagnosis of liver fibrosis, 0.92 (F≥2, p < 0.001), 0.84 (F≥3, p <
0.05) and 0.66 (F=4, p > 0.05), respectively.
Figure 4. Example of tissue elasticity distribution in a helathy subject represented as color-coded images over conven‐
tional B-mode image.
As for TE even for RTE obesity, narrow intercostal space and ascites are potential physical
limitations. More number of sample about chronic hepatitis with assessment by RTE is needed
to performed to certify its advantages.
Acoustic Radiation Force Impulse Elastography. Acoustic Radiation Force Impulse (ARFI)
imaging is a novel ultrasound-based elastography method that is integrated in a conventional
ultrasound machine enabling the exact localization of measurement site. ARFI imaging
involves the mechanical excitation of tissue using short-duration acoustic pulses (≈262 μsec)
with a fixed transmit frequency of 2.67 MHz to generate localized, micron-scale displacements
in tissue. The first available applications to implement this technology are Virtual Touch tissue
imaging and Virtual Touch tissue quantification (Siemens, Erlangen, Germany). Unlike
conventional B-mode sonography, which provides anatomical details based on differences in
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acoustic impedance, Virtual Touch™ imaging describes relative physical tissue stiffness
properties. In complement, Virtual Touch™ tissue quantification provides accurate numerical
measurements related to tissue stiffness at user-defined anatomical locations. ARFI technology
quantifies stiffness without manual compression since, using the Virtual Touch™ application,
the tissue is compressed by acoustic energy. Virtual Touch tissue quantification is a quantita‐
tive assessment of tissue stiffness, through measurement of shear wave speed.
The system uses a standard ultrasonographic probe and offers elastography with a flexible
metering box of 1 cm at variable depths (Figure 5). An acoustic push pulse transmitted by the
transducer (3.5 MHz) toward the tissue induces an elastic shear wave that propagates through
the tissue (Figure 6). The propagation of the shear wave is followed by detection pulses that
are used to measure the velocity of shear wave propagation, which is directly related to tissue
stiffness: speed increases with stiffness. The measurements were performed on the right lobe
of the liver through the intercostal spaces, away from motion and portal/hepatic vessels, about
2 cm from the liver capsula, at a depth between 3.8 and 5.5 cm. Usually a total of 10 valid
measurements per patient are performed. In difficult patients, to obtain better access to the
liver without excessive pushing or breath holding, the measurements were performed on
patients lying in the left lateral decubitus position, or using a subcostal approach to the left
lobe. The results are expressed by the shear wave velocity - SWV (m/s). Thus, the measured
SWV is an intrinsic and reproducible property of the tissue [54-56].
According to Sporea et al., [57] despite exhibiting a strong correlation with histological fibrosis,
ARFI is an accurate test only for the prediction of severe fibrosis and cirrhosis (F=4) using 1.7
m/s as cut-off value (AUROC: 0.931, sensibility: 93%, specificity: 86.7%). Recently, a meta-
Figure 5. Measurement of the shear wave velocity with ARFI. The region of interest is placed 2–3 cm from the liver
capsule at the right hepatic lobe, where the liver tissue is at least 5.5 cm thick.
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analysis was performed [58] including ARFI patient data obtained from eight studies for a total
of 518 patients. The authors found that the AUROC was 0.87 for the diagnosis of significant
fibrosis (F≥2), 0.91 for the diagnosis of severe fibrosis (F≥3), and 0.93 for the diagnosis of
cirrhosis. The optimal cut-off for F≥2 was 1.34 m/s, for F≥3 1.55 m/s and for the diagnosis of
liver cirrhosis 1.80 m/s, respectively.
Finally, Colombo et al. [59] performed a head-to-head comparison of TE, RTE, and ARFI
imaging in the diagnosis of liver fibrosis, in a population consisting of 27 normal subjects and
54 patients with CLD. The three methods showed high correlation with fibrosis and poor
correlation with necro-inflammatory activity, with TE showing the best performance (AUROC
was 0.87 for F≥1 and 0.89 for F≥2, with the best cut-offs set at 6.3 kPa for fibrosis and 7.8 kPa
for significant fibrosis). Only TE and ARFI exhibited high diagnostic accuracy (AUROC ≥ 0.9)
in diagnosing cirrhosis (F=4). However, TE was unsuccessful in 15% of patients, mainly due
to obesity. Nevertheless, the authors conclude that TE is probably the best method to screen
for CLD patients in the general population and to identify significant fibrosis, but further
studies are needed to fully explore the potential of RTE, since its technology and the equations
used to calculate tissue elasticity are rapidly changing.
4.2. MR imaging-based techniques for assessment of liver fibrosis
In the last decade, the development of MRI scanner with high-performance magnetic field
gradients made the introduction of three-dimensional sequences for liver imaging possible.
Volumetric image acquisitions with near-isotropic voxels (1–3 mm in all three-dimensions)
through the entire liver can be achieved in a single breath-hold or using respiratory triggering.
In detail, several technological advances have been made for assessment of fibrosis, including
Conventional MRI, Double contrast-material enhanced MRI, Diffusion-weighted MRI, MR
elastography, perfusion MRI, and MR spectroscopy.
Figure 6. Principle of Acoustic Radiation Force Elastography. Transmission of short-duration acoustic pulses generates
tissue displacement within a localized area of the liver, resulting in shear waves propagating away from the region of
excitation. Shear wave velocity is measured in meters/s within a defined region of interest (ROI), and is proportional to
the square root of tissue elasticity.
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Unenhanced MRI. In patients with precirrhotic stages of liver fibrosis as well as patients with
early cirrhosis, the liver parenchyma usually has a normal appearance or may reveal only
subtle, generic heterogeneity on unenhanced MRI [60]. Conversely, in patients with advanced
cirrhosis, fibrotic septa and bridges show low-signal-intensity reticulations on T1-weighted
images and high signal-intensity reticulations on T2-weighted images (Figure 7) [61]. Dodd et
al. [62] described four different patterns of diffuse fibrosis detectable on T2-weighted images:
(1) patchy, poorly defined regions of high signal intensity, (2) thin perilobular bands of high
signal intensity, (3) thick bridging bands of high signal intensity that surround regenerative
nodules, and (4) diffuse fibrosis that causes perivascular (bull’s-eye) cuffing. Although most
forms of diffuse fibrosis can occur in any type of cirrhosis, thin perilobular bands and peri‐
vascular cuffing appear most commonly in primary biliary cirrhosis. The large water content
of advanced fibrosis provides prolonged T2 relaxation times and may explain these signal
intensity characteristics [63]. These reticulations frequently enclose regenerative nodules,
which are <2 cm and isointense to hyperintense on T1-weighted images, isointense to hypo‐
intense on T2-weighted images. Lipid-containing nodules or steatotic nodules display signal
loss on out-of-phase gradient echo (GRE) images in comparison with in-phase images. Iron
containing nodules or siderotic nodules appear markedly hypointense on T2-weighted and
T2*-weighted images [63].
Figure 7. Unenhanced MR imaging in a in a 61-year-old man with alcohol-related cirrhosis. Unenhanced T1-weighted
image (a) shows hypointense reticulations (arrows) and numerous regenerative nodules (arrowheads), which are iso-
to hyperintense. Unenhanced T2-weighted fat-saturated image (b) allows a clearer visualization of the reticulations
throughout the liver parenchyma visible as hyperintense septa (arrows).
Fibrotic scars up to several centimetres thick characterize confluent fibrosis with a mass-like
appearance seen in approximately 15% of patients with advanced cirrhosis. Confluent fibrosis
has similar signal intensity as fibrotic septa and bridges but is easier to visualize because of its
size. This mass-like fibrosis typically has a wedge-shaped area, radiates from the portal hilum,
contacts and retracts the liver capsule, and causes focal volume loss.
Furthermore, the cirrhotic liver develops characteristic morphologic alterations such as surface
nodularity, widening of fissures, expansion of the gallbladder fossa, notching of the right lobe,
atrophy of the right lobe, and relative enlargement of the lateral segments of the left lobe and
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caudate lobe (Figure 8) [62]. However, these signs of advanced disease have high specificity for
cirrhosis but there are only few publications on unenhanced MRI for the staging of hepatic fibrosis.
Figure 8. Axial Balanced fast field echo image in a 59-year-old man with alcoholic cirrhosis shows surface nodularity,
hypertrophy of the left lobe, expanded gallbladder fossa (asterisk), and notching of the right lobe (arrow).
Contrast-enhanced MRI. The detection of liver fibrosis is improved by the administration of
contrast agents. Three contrast agents are currently commercially available: gadolinium-based
contrast agents; superparamagnetic iron oxide particles; Gd-EOB-DTPA.
Gadolinium-based contrast agents cause T1 shortening and signal enhancement on T1-
weighted images. Most gadolinium-based contrast agent formulations freely equilibrate with
the extracellular compartment and accumulate in tissues with large extracellular volumes such
as liver fibrosis [64]. Thus, most gadolinium-based contrast agents preferentially enhance the
signal of liver fibrosis on T1-weighted images. The reticulations enhance progressively after
contrast agent administration. Although some of the reticulations are enhanced at the arterial
phase, most are not enhanced until the more delayed images (late venous and equilibrium
phases) (Figure 9). Similarly, the persistence of enhancement of the confluent fibrosis into the
late phases associated with its characteristic morphology allows differentiation from HCC.
Superparamagnetic iron oxide particles (SPIO) are reticulo-endothelial-specific particulate
MRI contrast agents which are cleared from the blood through phagocytosis and accumulate
in the cells of the reticulo-endothelial system of the liver, spleen, and bone marrow, with
approximately 80% taken up by the liver. SPIO markedly shorten T2 relaxation rates and signal
loss is greatest with gradient recalled echoes because these are highly sensitive to T2*-
shortening effects. Consequently, the signal intensity of the liver parenchyma decreases on T2-
weighted sequences, except in the areas with reduced Kupffer cell density, like fibrosis within
the liver, which accumulate less iron oxide and appear as high signal-intensity reticulations
(Figure 10) [65]. Two SPIO particle formulations are clinically available, namely ferumoxides
and ferucarbotran. Ferumoxides (Feridex IV, Berlex Laboratories; and Endorem, Guerbet) is a
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SPIO colloid with low molecular weight dextran coating, with a particle size of 120-180 nm.
This contrast agent is prepared as a dilution in 100 ml of 5% dextrose and administered as a
drip infusion over about 30 min. At about 8 min following the intravenous injection, iron oxide
particles are taken up by the reticulo-endothelial cells in the liver and in the spleen. Maximum
signal loss is obtained after 1 h with an imaging window ranging from 30 min to 6 h after the
injection. The recommended dosage of Endorem (ferumoxides injectable solution) is 0.56
milligrams of iron (0.05 mL Feridex IV) per kilogram of body weight. Ferucarbotran (Resovist,
Bayer Healthcare) is a carboxydextrane-coated SPIO, with a hydrodynamic diameter ranging
between 45 and 60 nm. Unlike Endorem, Resovist can be safely injected rapidly in a bolus
fashion, and has an effect on the shortening of both T1 and T2 relaxation time. Dynamic T1-
weighted GRE 3D sequences can be performed to acquire the perfusion properties of the lesion
during the arterial and portal venous phases of the contrast agent. On dynamic MR imaging
using T1-weighted GRE, enhancement was positive in the liver for at least 30 s after bolus
injection of SPIO. On delayed images after 10 min, the T2/T2* effects are observed due to the
reticulo-endothelial uptake in the liver. The recommended dose of Resovist is: for patients
weighing less than 60 kg: 0.9 ml Resovist); for adults patients weighing 60 kg or more: 1.4 ml
Resovist. Lucidarme et al. describe hypersignal intensities on the SPIO enhanced T2-weighted
sequences in 76% of patients with chronic hepatitis and a Metavir score of F≥2 with good
specificity (80%) [66]. It is hypothesized that reticulation patterns surrounding hypointense
SPIO enhanced liver tissue correspond to fibrotic septa surrounding regenerative nodules [67].
Figure 9. Dynamic enhancement patterns in fibrous tissue after administration of a gadolinium-based contrast agent.
Axial 3D T1-weighted images obtained in the (a) arterial phase, (b) portal venous phase, and (c) 3 min after intrave‐
nous injection of a gadolinium-based contrast agent, show the progressive enhancement of the fibrotic reticulations
in the liver parenchyma.
Gd-EOB-DTPA, a derivative of gadopentetate dimeglumine (Gd-DTPA), known generically
as gadoxetic acid (Primovist, Bayer Schering, Berlin, Germany), is a recent hepatocyte-specific
MR contrast agent and has been used to detect and characterize various hepatic tumors [68,
69]. Similar to Gd-DTPA, Gd-EOB-DTPA can be used as bolus injection. This contrast agent is
actively transported from the sinusoidal space into liver cells and causes intense parenchymal
enhancement, beginning within 1 or 2 min of contrast agent injection. The enhancement peaks
at around 20 min and lasts for at least 2 h. Unlike Gd-DTPA, which will return into blood
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vessels thereafter and is excreted entirely by kidneys, about 50% of Gd-EOB-DTPA is secreted
through the biliary system, and the other 50% is secreted by kidney [70]. Deterioration of
hepatic function would decrease the excretion of Gd-EOB-DTPA, because it needs adenosine
triphosphate (ATP) for energy to secrete into the bile ducts by hepatocyte [71, 72]. In fact, in
livers with good hepatic function, intense enhancement occurs. In livers without good
function, due to cholestasis or hepatocellular dysfunction, enhancement of liver parenchyma
may be weak. Using this contrast medium liver fibrosis can appear as an area of low signal
intensity due to decreased hepatic function from fibrosis (Figure 11). Recent dynamic contrast-
enhanced MRI studies have shown promising results using Gd-EOB-DTPA. Lee et al. [73]
reported a significant alteration in signal intensity change between a group of patients with
liver cirrhosis or chronic hepatitis and healthy subjects in the hepatocyte phase 20 min after
contrast agent administration. In addition, Watanabe et al. [74] demonstrated that the contrast
enhancement index significantly correlated with fibrosis stage. Clinical trials are currently
under way to prospectively assess fibrosis staging with this contrast agent.
Figure 10. Advanced fibrosis and infiltrative HCC in a 46-year-old man with HCV-related cirrhosis. T2*-weighted gradi‐
ent-echo images obtained before (a) and after (b) intravenous SPIO injection. After injection, fibrotic reticulations in
the right lobe have diminished Kupffer cell density, do not accumulate iron oxides, and hence appear relatively hyper‐
intense (arrows in b). The left lobe is expanded and shows a wedge-shaped mass with heterogeneous hyperintensity
(arrowheads in b) in the hepatocellular phase, suggestive for infiltrative HCC.
Double-contrast enhanced MRI. Double-contrast MRI (DC-MRI) using extracellular contrast
agents in combination with SPIO particles was shown to sensitively detect liver fibrosis and
depict HCC in cirrhotic livers [75]. During DC-MRI, two contrast media boli with a synergistic
effect are applied: 1) SPIO particles infusion to observe the accumulation of SPIO particles by
Kupffer cells of normal liver parenchyma or by Kupffer cells located in benign liver lesions,
which causes signal loss on T2*-weighted images followed by 2) Gadolinium chelates i.v.
injection for analysis of delayed enhancement of hepatic septal and bridging fibrosis on T1-
weighted images with fat suppression. The consequence is high image contrast between the
low-signal-intensity liver parenchyma and high-signal-intensity fibrotic reticulations (Figure
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12) [76]. Aguirre et al. [77] examined 101 CLD patients who underwent DC-MRI to detect
hyperintense reticulations, which are postulated to represent septal fibrosis, and hypointense
nodules thought to represent regenerating nodules. They achieved an accuracy of greater than
90% for the diagnosis of advanced hepatic fibrosis (F≥3) compared with histopathological
analysis. Recently, Fischer et al. [78] assessed the performance of semiquantitative measure‐
ment of liver perfusion from analysis of SPIO induced signal-dynamics. In this study 31
patients, including 18 patients with biopsy proven liver cirrhosis, prospectively underwent
DC-MRI with dynamic T2*-weighted gradient echo imaging after SPIO bolus injection
measuring hepatic blood flow index (HBFI) and splenic blood flow index (SBFI). Significant
inverse correlation was seen between HBFI and presence of liver cirrhosis resulting in a
significant decrease of HBFI in patients suffering of cirrhosis compared with patients with
healthy livers (P < 0.05).
Figure 11. Confluent fibrosis in a 56-year-old man with cirrhosis. Precontrast (a), arterial phase (b, c), portal venous
phase (d), 3 min (e), 5 min (f), 8 min (g), and hepatocellular phase (h). Wedge-shaped ill-defined areas associated with
capsular retraction, with decreased enhancement in the dynamic phases and with no uptake of Gd-EOB-DTPA in the
HCP (arrows).
An advantage of DC-MRI is that it works on routine imaging units and does not require
specialized equipment. Computer-based texture analysis techniques may assess texture
abnormalities qualitatively or quantitatively. The high cost and inconvenience associated with
use of two contrast agents represent the main limitations of DC-MRI. Moreover, minor adverse
events have been associated with use of SPIO, such as back pain, which has been reported in
about 10% of cirrhotic patients during infusion of the particles. It is usually associated with
rapid injection of SPIO and resolves after the injection is paused [79].
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Figure 12. Double contrast-enhanced MR imaging appearance of cirrhosis in a 67-year-old woman with chronic HCV
infection. Axial 2D T1-weighted unenhanced image (a); axial 3D T1-weighted enhanced image 30 sec after ferucarbo‐
tran injection, thus exploiting the shortening effect on T1 relaxation time; (b), T2*-weighted gradient-echo SPIO-en‐
hanced image after 15 min (c); and axial 3D T1-weighted double contrast-enhanced image (d). SPIO and a
gadolinium-based contrast agent are synergistic with better depiction of fibrotic reticulations (arrows in d) and regen‐
erative nodules (arrowheads in d).
Diffusion weighted magnetic resonance imaging. Diffusion-weighted magnetic resonance
imaging (DW-MRI) is a technique that assesses the freedom of diffusion of water protons in
tissues and has been extensively applied for the early detection of cerebral ischemia. Recent
advances have made it feasible to apply diffusion MRI techniques for abdominal imaging [80].
In liver fibrosis, extracellular collagen fibers, glycosaminoglycans and proteoglycans may
inhibit molecular diffusion of water, which suggest that DWI can be an effective method for
the evaluation of fibrosis.
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In DW images the observed signal intensity of tissue varies inversely with the freedom of
water proton diffusion. Tissues with reduced water proton diffusion will be brighter than
those with normal water proton diffusion. The sensitivity of the imaging sequence to water
diffusion can be  altered by changing the  b  value,  or  b  factor,  which is  dependent  in  a
specific  mathematical  way  on  the  diffusion  encoding  gradient  waveforms  [81]  and
increases with the duration and amplitude of the diffusion sensitizing gradients. If two or
more  DW  images  are  obtained,  then  it  is  possible  to  calculate  the  apparent  diffusion
coefficient (ADC) of water protons in tissues, which is determined by the slope of the log
intensity versus b value [82, 83]. Because of the relatively short T2 relaxation time of the
normal liver parenchyma (approximately 46 msec at 1.5 T and 24 msec at 3.0 T) [84], the
b values used for clinical imaging are typically no higher than 1000 sec/mm2. Applying a
small diffusion weighting of b less than 100–150 sec/mm2  nulls the intrahepatic vascular
signal, creating the so-called black-blood images, which improves detection of focal liver
lesions [85, 86], while higher b values (≥ 500 sec/mm2) give diffusion information that helps
assessment of liver cirrhosis and focal liver lesion characterization [87]. The calculated ADC
values can be displayed as an image and quantitative analysis can be performed by placing
measuring the mean value within a region of interest, which is typically positioned in the
right hepatic parenchyma to avoid major vascular structures and cardiac motion artifacts
(Figure 13).
Because DW images were acquired using different b values and protocols and likely different
patient populations, ADC values of cirrhosis are not consistent throughout the literature.
Examples include ADC cutoff values of 1.41 × 10−3 mm2/s by Taouli et al. [88], 0.88 × 10−3 mm2/
s by Kim et al. [89], 1.11 × 10−3 mm2/s by Girometti et al. [90], and more recently 1.63 × 10−3
mm2/s by Kovač et al. [91]. Although there are various ADC values for the diagnosis of
cirrhosis, the cirrhotic liver tissues consistently have significantly lower ADC values compared
with liver tissues with no fibrosis as seen in prior studies [92-94]. Previously published studies
with DWI showed moderate sensitivity and specificity in distinguishing advanced fibrosis to
cirrhosis (F3–F4) from lesser degrees of fibrosis. However, considerable overlap in ADC values
between tissues with cirrhosis and with no to moderate fibrosis was also observed.
In a recent study, Bakan et al. [95] performed DWI with b-factors of 0, 500 and 1000 s/mm2
in order to investigate the relationship between ADC values and liver inflammation (HAI
scores).  They  found  that  as  HAI  scores  increased  there  was  a  statistically  significant
decrease in ADC values (P<0.01).  However,  differences in MRI equipment and sequence
parameters  make it  difficult  to  compare studies.  In  addition,  despite  technical  improve‐
ments  in  DWI,  the  method  remains  sensitive  to  susceptibility  and  motion-related  arti‐
facts,  and it  is  difficult  to  obtain  images  with  sufficient  quality  for  reliable  quantitative
analysis on a consistent basis. Further studies are required to create a standard setup for
DWI to make studies comparable and to evaluate how various ADC values of liver tissue
other  than  fibrosis  may  be  influenced  by  other  factors  associated  with  chronic  liver
diseases.
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Figure 13. year-old man with biopsy-proven hepatitis C and related stage III fibrosis. Diffusion-weighted images ob‐
tained with b value of 0 (a) and 800 (b) s/mm2 and apparent diffusion coefficient (ADC) map (c) are shown. Mean ADC
value was 0.98 × 10−3 mm2/s.
MR Elastography. A new option for assessing shear stiffness in various tissue types, including
liver fibrosis, is MR Elastography (MRE) [96]. MRE uses a modified phase contrast technique
to sensitively image the propagation characteristics of acoustic shear waves that are generated
with the organ of interest [97]. This system consisted of an acoustic driver system, a gradient-
echo MRE pulse sequence, and special software for data analysis. A 19cm diameter, 1.5cm thick
cylindrical passive driver is placed against the right chest wall over the liver with the center
of the driver at the level of the xiphoid of the sternum (Figure 14). The passive driver is held
in place with an abdominal binder. Continuous acoustic vibration at frequencies between 40
and 120 Hz transmits from an active driver to the passive driver through a flexible vinyl tube
was used to produce propagating shear waves in the liver [98-100]. When the pneumatic device
is activated, the patient will feel vibrations in the rib cage due to the pressure waves. MR images
are acquired with a gradient-echo sequence as the waves propagate through the liver. The
velocity and wavelength of the waves propagating in the abdomen depend on the stiffness of
the tissue (velocity and wavelength increase with greater tissue stiffness), enabling the stiffness
estimation [101].
A specialized phase-contrast MRI sequence is then used to image the propagating waves in
the liver. This sequence uses motion-encoding gradients that are oscillated synchronously with
the applied vibrations, allowing waves with amplitudes in the micron range to be readily
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imaged. Each MRE acquisition provides an image that represents the displacement caused by
shear wave propagation in the medium. The wave images are then processed using a specially
developed inversion algorithm to generate quantitative images called elastograms [96].
Elastograms are maps of tissue stiffness shown on a color scale ranging from soft to hard. Mean
elasticity values measured in regions of interest within the liver are obtained. The unit of
measurement for elasticity is kilopascal (kPa), as it is with ultrasound-based transient elas‐
tography (TE) (Figure 15). Each MRE examination is performed during a single breath-hold
of 10 to 30 seconds to allow imaging of wave propagation, in addition to the standard 30-40
minute MRI examination of the abdomen [102].
Initial studies in patients with a spectrum of liver disease types have shown that liver stiffness
as measured with MRE increases as the stage of fibrosis advances. The differences in stiffness
between patients with early stages of fibrosis (F0 vs F1 vs F2) are small and there is overlap
between groups, but the differences between groups with higher stages (F2 vs F3 vs F4) are
large, with little overlap between groups [99, 102].
As for ADC values in DWI examinations, a variety of MRE cutoff values are observed
throughout the literature. In a recent study, to identify fibrosis stage ≥ 2 (F2–F4) and stage ≥ 3
(F3–F4), Wang et al. [103] reported sensitivity of 91% and 92% and specificity of 97% and 95%
with cutoff values of 5.37 and 5.97 kPa, respectively. Huwart et al. [104] showed similar high
sensitivity of 98% and 95% and specificity of 100% and 100% for discrimination, although
relatively lower cutoff values of 2.5 kPa and 3.1 kPa were used. The variability of cutoff values
observed may be potentially explained by MRE different scanner manufacturers, case mixes,
imaging protocols, and post-processing procedures.
As reported by Rustogi et al. [105] stiffness measurements are repeatable with high overall
inter-reader agreement (P=0.74); thus, MRE shows potential for longitudinal monitoring of
patients. Furthermore, Yin et al. found that this technique has a high negative predictive value
(97%) for excluding the presence of fibrosis, suggesting that MRE could have a role for
improving the ability to risk-stratify patients for liver biopsy [102].
MRE benefits from the intrinsic advantages of MR imaging, such as freely oriented field of
view, no “acoustical window” requirement, the ability to quantify steatosis, operator inde‐
pendence, and the ability to perform conventional liver MRI at the same time. In addition,
MRE is relatively unaffected by the patient’s body habitus and the presence of ascites, as shear
waves generated in vivo in MRE have good hepatic penetration.
Nevertheless MRE has some limitations. The most important one is that MRE measures a
surrogate of liver fibrosis (tissue stiffness) rather than fibrosis itself. A variety of factors may
confound MRE assessment of liver fibrosis, including hepatic inflammation, steatosis, hepatic
vascular congestion, cholestasis, and portal hypertension. Moreover, the selection of signifi‐
cant regions of interest is subjective and requires judgment and experience. As with the other
techniques, efforts to standardize the equipment and techniques used for MRE should be
practiced to maximize diagnostic accuracy and enable comparison of results in different
settings. Further prospective evaluation is required for characterizing the diagnostic perform‐
ance of MRE.
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Perfusion MRI. Perfusion MRI provides a method of measuring perfusion changes in the liver.
Liver fibrosis gradually led to a loss of normal fenestrae, due to deposition of basement
membrane and new formation of capillary tight junctions along the sinusoids (phenomenon
of capillarization). There is also deposition of fibers by activated hepatic stellate cells, which
results in enlargement of the Space of Disse. Consequently, intrahepatic vessels and sinusoids
Figure 14. A remote acoustic driver pumps air into a pneumatic device strapped onto the patient’s body, eliciting tis‐
sue displacement, which is measured by MRE and used to derive images showing tissue stiffness.
Figure 15. An elastogram of a healthy liver (a) showing a post processed value of 1.98 kPa corresponding to normal
tissue stiffness. An elastogram of the liver of a patient with Grade 3 fibrosis (b), with a shear stiffness value of 6.95 kPa.
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obliteration reduces passage of blood through the parenchyma, producing increase in hepatic
arterial perfusion and decrease in portal venous perfusion. Several studies have shown that
careful kinetic modeling of dynamic contrast-enhanced (DCE) MR images can noninvasively
quantify regional and global changes in hepatic perfusion associated with liver cirrhosis and
fibrosis [106-109].
For perfusion MRI of the liver, a rapid injection of a low-molecular-weight gadolinium-chelate
contrast is necessary, using a programmable pump injector. Is recommended the intravenous
administration of Gd-DTPA (0.1-0.2 mmol of contrast medium/kg body weight) followed by
a 20ml saline flush, at an injection rate of 3–5 ml/s. T1-weighted 3D spoiled gradient echo
sequence is typically performed, with whole liver coverage and high temporal resolution (i.e.
repeated imaging of the same area in the liver about every 4 s). An oblique imaging plane
(oblique coronal) is particularly useful in order to include the aorta and the portal vein in the
same image sections. Patients are generally instructed to fast for 4–6 h prior to the scan, given
the potential changes in portal venous flow occurring in the post-prandial state.
The analysis can be performed by semi-quantitative or quantitative techniques. One semi-
quantitative description of liver vascularity is the hepatic perfusion index (HPI), which
describes the relative contribution of arterial vs portovenous flow to the total liver perfusion.
The HPI has been investigated using different imaging techniques, and appears to provide
biologically meaningful information despite its relative simplicity [110]. For quantitative
methods, regions of interest (ROIs) are placed over the area of interest to generate signal
intensity (SI) versus time curve. Typically, arterial input function is obtained by placing a ROI
on the abdominal aorta. Portal input function is obtained from a ROI placed on the main portal
trunk, and a ROI at the level of hepatic parenchyma to measure the time–activity curve. Several
kinetic models are currently in use for the assessment of liver perfusion. Single-input models
assume that the vascular input is derived from the hepatic artery only, whereas dual-input
models assume that the vascular input is derived from both the hepatic artery and the portal
vein. Single compartment models assume that the contrast is confined to only one compart‐
ment (i.e. vascular space), whereas dual compartment models assume that there is dynamic
distribution of contrast between two compartments (i.e. the vascular space and the interstitial
space). Therefore, numerous perfusion parameters can be estimated, including absolute portal
venous blood flow, absolute arterial blood flow, absolute total liver blood flow, portal venous
fraction, arterial fraction, distribution volume (DV), and mean transit time (MTT) [111].
In a previous study, Annet et al. [106] have investigated a dual-input single compartment
model and have demonstrated altered arterial, portal and total liver perfusion, as well as
increased MTT in cirrhotic livers compared to non-cirrhotic livers, and found a correlation
with severity of disease as assessed by the Child-Pugh class and degree of portal hypertension.
In a recent study, Leporq et al. [112] applied dual-input single-compartment model and
quantitative perfusion parameters for the noninvasive assessment of liver fibrosis. HPI, arterial
and portal perfusion, tissue blood volume, and MTT showed a significant difference between
nonadvanced fibrosis (F0–F2) and advanced fibrosis (F3–F4). In addition, HPI and portal
perfusion showed a strong correlation with the fibrosis score (P < 0.001). Chen et al. performed
a prospective study using Gd-EOB-DTPA in patients with chronic hepatitis to calculate
Practical Management of Chronic Viral Hepatitis132
perfusion parameters by applying a dual-input single compartment model. They found a
significant increase in arterial perfusion at 60 s and 100 s in patients compared with healthy
subjects and a significant difference in arterial perfusion when three different fibrotic sub‐
groups (none, mild and advanced) were compared at 60 s [113].
Several factors limit the correlation between perfusion parameters and fibrosis, such as cardiac
status, fasting state, hepatic congestion, hepatic inflammation, hepatic lesions, and portal
venous flow. Other limitations include differences in technical parameters, imaging system,
and use of different pharmacokinetic models [114]. In addition, relevant is the laborious post-
processing required to obtain quantitative perfusion parameters. However, standardization
of imaging acquisition and analysis techniques need to be actively addressed for the technique
to be widely adopted.
MR Spectroscopy. MR spectroscopy (MRS) enables the non-invasive measurement of concen‐
trations of different chemical components within tissues, which are displayed as a spectrum
with peaks consistent with the various chemicals detected. The liver is considered an ideal organ
for MRS investigation due to its anatomical location and increased metabolic demands [115, 116].
MRS of the liver is performed using a whole body MRI system at field strengths of 1.5 Tesla (T)
or higher. The patient lies supine on the MRI table with RF coils positioned appropriately. After
a standard MR imaging for localization, special MR pulse sequences are applied to generate
spectroscopic data within the appropriate anatomical location and volume (defined by voxels)
of interest. A typical examination will take 45 to 60 minutes. The spectral analysis of data requires
processing to reduce noise and perform analysis. Metabolite concentrations can be expressed in
absolute or relative terms. In general, the peak area of a metabolite signal is directly related to
its concentration. Whereas a number of in vivo studies have explored the diagnostic perform‐
ance of MRS for characterizing hepatic lesions [117], more recently there has been some interest
in the role of MRS for detecting hepatic fibrosis. MRS is most commonly used to assess signals
from hydrogen (1H) and phosphorus (31P).
1H-based MRS is widely used for the quantification of hepatic lipid. In vitro MRS studies of
oils [118] and intact liver tissue [119] have demonstrated that lipid resonances might be
quantified to derive indices of lipid composition, including saturation and polyunsaturation.
These compositional indices differed between obese patients with and without hepatic
steatosis. Indices of lipid composition using in vivo proton (1H) MRS at 1.5 Tesla have been
shown to delineate the severity of fibrosis in patients with chronic hepatitis C (in whom hepatic
steatosis is prevalent) [120]. In patients with chronic HCV infection, as fibrosis advances,
steatosis tends to recede [121]. McPherson et al. [122] confirmed this inverse relation and found
that with 1H-MRS, the percentage of steatotic hepatocytes in patients with more advanced
fibrosis tended to be underestimated. However, because 1H-MRS yields an estimate of proton
density fat fraction and not a measure of the degree of hepatocellular involvement, this result
would be expected. When ROCs were generated for the diagnosis of steatosis with 1H-MRS
according to fibrosis stage, the values were only slightly lower in cases of more advanced
fibrosis (AUC, 0.97 for F=0–1 vs 0.95 for F=2–3). More recently, Georgoff et al. [123] also found
only a small decrease in the ROC for 1H-MRS in subjects with fibrosis (AUC, 0.96 for F=0 vs
0.92 for F=1–4).
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31P-based MRS has also shown promise as a method of assessing the degree of hepatic fibrosis,
in particular through analysis of the phosphomonoester/phosphodiester (PME/PDE) ratio [124].
As the stage of fibrosis increases, the PME peak may represent extensive membrane remodel‐
ing due to elevated levels of cell membrane precursors (such as phosphocholine and phosphoe‐
thanolamine). At the same time, there is a reduction in the PDE peak owing to reduced levels of
membrane degradation products such as glycerophosphorylethanolamine and glycerylphos‐
phorylcholine. Therefore, changes in the PME/PDE ratio are thought to reflect an increase in the
regenerative efforts made by the damaged liver [125]. Moreover, 31P-MRS had a sensitivity and
specificity of  82% and 81% respectively for  cirrhosis  and showed statistically  significant
differences between mild hepatitis, moderate hepatitis, and cirrhosis [126].
Several limitations with current MRS approaches, however, are observed. The major problem
in obtaining MRS signals from abdominal organs is sensitivity to physiologic movement
during the scan time usually exceeding several minutes. Various methods of reducing
movement, such as breath holding and placing patients in the prone position during signal
acquisition, have been used [127]. Furthermore MRS requires considerable operator skills
(sequence programming, shimming, analysis of spectra) and access to special equipment. Most
studies contain small numbers of patients from heterogeneous populations assessed by
varying MRS methods. In addition, the variation in reproducibility of data acquisition from
healthy volunteers can range between 4% and 20% for both subject and examination. Ulti‐
mately, the role of in vivo MRS for detecting hepatic fibrosis requires assessment in larger
diagnostic accuracy studies among patients with various hepatobiliary disorders.
5. Conclusion and future directions
A fast, safe and reliable technique to assess fibrosis of CLD and to follow up progression or
regression of fibrosis during treatment is required. Ultrasound is still a widespread, low cost,
user-friendly, and accurate technique. However, it may not have a high specificity due to
limitations related to the patient or operator and its role is probably more oriented to patient’s
selection and follow-up. MRI is a more "challenging" method for radiologists and especially
for patients, with limitations related to: the availability of high performance scanner; the
presence of experienced personnel; the examination’s timing and to its less tolerability. MRI
may, however, represent the one-stop shop technique, allowing the diagnosis and character‐
ization of fibrosis but also the overall assessment of CLD. In addition, MRI is more research-
oriented, since its multiparametric potential, allows not only distinguishing the various fibro-
steatosic alterations but also performing metabolic assessments. This last feature permits
studies on the pathogenetic mechanisms and on drug therapies studies.
The diagnostic performances of all described noninvasive radiologic modalities were better in
distinguishing patients with cirrhosis from lesser degrees of fibrosis. However, staging of
fibrosis was rarely achieved reliably. In conclusion, to date, the most promising techniques
appear to be Transient Elastography [59] and MRE [128, 129] since they provide reliable results
in detecting severe fibrosis and future developments promise to increase the reliability and
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accuracy of staging of hepatic fibrosis. In the future, MRI technical development and newcontrast agents could permit imaging of fibrogenesis.
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